{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:26:15Z","timestamp":1788445575175,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.transci.2023.103661","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T20:52:24Z","timestamp":1677617544000},"page":"103661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic plasma exchange-free treatment for first-episode TTP: A systematic review"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5580-6664","authenticated-orcid":false,"given":"Jiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-5751","authenticated-orcid":false,"given":"Bin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2023.103661_bib1","first-page":"11","article-title":"Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura","author":"Hanlon","year":"2020","journal-title":"Therapeutic Adv Hematol"},{"key":"10.1016\/j.transci.2023.103661_bib2","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transci.2023.103661_bib3","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.4045\/tidsskr.15.1272","article-title":"Congenital thrombotic thrombocytopenic purpura","volume":"136","author":"Krogh","year":"2016","journal-title":"Tidsskr Nor Laege"},{"key":"10.1016\/j.transci.2023.103661_bib4","first-page":"22","article-title":"Acquired autoimmune thrombotic thrombocytopenic purpura","volume":"49","author":"Vacca","year":"2019","journal-title":"Nursing"},{"key":"10.1016\/j.transci.2023.103661_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2023.103661_bib6","first-page":"1","article-title":"Effectiveness of caplacizumab nanobody in acquired thrombotic thrombocytopenic purpura refractory to conventional treatment","author":"Palanques-Pastor","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.transci.2023.103661_bib7","first-page":"10","article-title":"Post approval experience with caplacizumab for acquired thrombotic thrombocytopenic purpura at a single institution","author":"Logothetis","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.transci.2023.103661_bib8","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/trf.15823","article-title":"Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma","volume":"60","author":"Irani","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2023.103661_bib9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jca.21877","article-title":"Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpura","volume":"36","author":"Perrone","year":"2021","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2023.103661_bib10","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/jth.15045","article-title":"Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab","volume":"18","author":"Volker","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2023.103661_bib11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0002-9343(87)90753-4","article-title":"High incidence of relapses in thrombotic thrombocytopenic purpura.\u00a0Clinical study of 38 patients","volume":"83","author":"Rose","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.transci.2023.103661_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2023.103661_bib13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1046\/j.1365-2141.2003.04049.x","article-title":"Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias","volume":"120","author":"Allford","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2023.103661_bib14","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3324\/haematol.2019.222083","article-title":"Transition from fresh frozen plasma to solvent\/detergent plasma in the Netherlands: comparing clinical use and transfusion reaction risks","volume":"105","author":"Saadah","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.transci.2023.103661_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2019.07.002","article-title":"Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced solvent\/detergent fresh frozen plasma for the treatment of thrombotic microangiopathy: the first French experience in a single center","volume":"59","author":"Poullin","year":"2020","journal-title":"Transfus Apher Sci."},{"key":"10.1016\/j.transci.2023.103661_bib16","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/trf.13229","article-title":"Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study","volume":"55","author":"Toussaint-Hacquard","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2023.103661_bib17","first-page":"183","article-title":"[Thrombotic thrombocytopenic purpura]","author":"Hansen","year":"2021","journal-title":"Ugeskr Laege"},{"key":"10.1016\/j.transci.2023.103661_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jca.21336","article-title":"Safety and efficacy of cryoprecipitate-poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single center retrospective evaluation","volume":"29","author":"Stefanello","year":"2014","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2023.103661_bib19","first-page":"175","article-title":"Cryoprecipitate-poor plasma fraction (cryosupernatant) in the treatment of thrombotic thrombocytopenic purpura at onset. A report of four cases","volume":"81","author":"Perotti","year":"1996","journal-title":"Haematologica"},{"key":"10.1016\/j.transci.2023.103661_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2141.2005.05418.x","article-title":"Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet","volume":"129","author":"Rock","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2023.103661_bib21","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/tme.12407","article-title":"Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient","volume":"27","author":"Sam","year":"2017","journal-title":"Transfus Med"},{"key":"10.1016\/j.transci.2023.103661_bib22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/jca.20150","article-title":"Successful management of a Jehovah's witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange","volume":"22","author":"Dabak","year":"2007","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2023.103661_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jca.21325","article-title":"Successful management of thrombotic thrombocytopenic purpura in a Jehovah's Witness without plasma exchange","volume":"30","author":"Chai","year":"2015","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2023.103661_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/jca.21710","article-title":"Survival of a Jehovah's Witness with thrombotic thrombocytopenic purpura without using plasma: a case report and review of the literature","volume":"34","author":"Baseri","year":"2019","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2023.103661_bib25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2023.103661_bib26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1006\/bcmd.2002.0522","article-title":"Rituximab therapy for refractory thrombotic thrombocytopenic purpura","volume":"28","author":"Gutterman","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.transci.2023.103661_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.transci.2023.103661_bib28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.transci.2023.103661_bib29","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s40265-018-0989-0","article-title":"Caplacizumab: first global approval","volume":"78","author":"Duggan","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.transci.2023.103661_bib30","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2023.103661_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2023.103661_bib32","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2147\/DDDT.S134470","article-title":"Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura","volume":"13","author":"Elverdi","year":"2019","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.transci.2023.103661_bib33","first-page":"59","article-title":"Reversible posterior leukoencephalopathy syndrome in a case of adult onset Still's disease with concurrent thrombotic thrombocytopenic purpura: response to high dose immunoglobulin infusions","volume":"60","author":"Khobragade","year":"2012","journal-title":"J Assoc Phys. India"},{"key":"10.1016\/j.transci.2023.103661_bib34","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2169\/internalmedicine.52.9180","article-title":"Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin","volume":"52","author":"Nishijima","year":"2013","journal-title":"Intern Med"},{"key":"10.1016\/j.transci.2023.103661_bib35","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/bmt.2009.242","article-title":"Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin","volume":"45","author":"Sakai","year":"2010","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103661_bib36","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:56:07Z","timestamp":1761468967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050223000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1473050223000289"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2023.103661","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic plasma exchange-free treatment for first-episode TTP: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2023.103661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103661"}}